Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18668012 | COVALENT MULTI-SPECIFIC ANTIBODY | May 2024 | September 2024 | Allow | 4 | 0 | 0 | Yes | No |
| 18304172 | Engineered Human IL-21 Cytokines and Methods for Using the Same | April 2023 | April 2024 | Allow | 12 | 1 | 1 | Yes | No |
| 18017282 | IL12RB1-BINDING MOLECULES AND METHODS OF USE | January 2023 | August 2023 | Allow | 7 | 0 | 1 | Yes | No |
| 17541854 | ALLERGY THERAPY | December 2021 | July 2024 | Abandon | 31 | 4 | 1 | No | No |
| 17530800 | METHODS OF TREATING ASTHMA WITH POLYPEPTIDES TARGETING IL-13 AND TSLP | November 2021 | July 2023 | Allow | 20 | 0 | 0 | Yes | No |
| 17473710 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE | September 2021 | September 2024 | Abandon | 36 | 0 | 1 | No | No |
| 17389533 | Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody | July 2021 | April 2024 | Abandon | 33 | 2 | 1 | No | Yes |
| 17373414 | IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF | July 2021 | June 2024 | Abandon | 36 | 0 | 1 | No | No |
| 17373426 | IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF | July 2021 | December 2023 | Abandon | 29 | 0 | 1 | No | No |
| 17373422 | IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF | July 2021 | August 2024 | Abandon | 37 | 0 | 1 | No | No |
| 17320174 | PARTIAL AGONISTS OF INTERLEUKIN-2 | May 2021 | June 2024 | Allow | 37 | 4 | 1 | Yes | No |
| 17317782 | POLYPEPTIDES WITH ALTERED BINDING TO NEONATAL FC RECEPTOR (FCRN) AND METHODS OF USE | May 2021 | April 2022 | Allow | 11 | 2 | 1 | Yes | No |
| 17238549 | Antibodies to IL-34 | April 2021 | January 2023 | Allow | 20 | 0 | 1 | Yes | No |
| 17234005 | ACTIVATABLE FUSION PROTEIN AND USE THEREOF | April 2021 | March 2024 | Allow | 35 | 1 | 1 | Yes | No |
| 17208046 | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP | March 2021 | August 2021 | Allow | 5 | 1 | 1 | Yes | No |
| 17175129 | Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody | February 2021 | September 2023 | Abandon | 31 | 2 | 1 | Yes | No |
| 17165729 | METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS | February 2021 | October 2022 | Abandon | 21 | 2 | 1 | Yes | No |
| 17165724 | METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS | February 2021 | November 2023 | Abandon | 33 | 3 | 1 | Yes | Yes |
| 17162924 | METHODS FOR TREATMENT OF MICROBIAL DISORDERS | January 2021 | June 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17155773 | IL-21 ANTIBODIES | January 2021 | October 2023 | Abandon | 33 | 0 | 1 | No | No |
| 17127738 | METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS | December 2020 | April 2024 | Abandon | 40 | 4 | 1 | Yes | Yes |
| 17127758 | METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS | December 2020 | November 2022 | Abandon | 23 | 2 | 1 | No | Yes |
| 17122752 | EXPRESSION VECTOR ENCODING ANTIBODY MOLECULE WHICH BINDS IL-17A AND IL-17F | December 2020 | October 2023 | Allow | 34 | 1 | 0 | Yes | No |
| 17115906 | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP | December 2020 | November 2022 | Abandon | 23 | 0 | 1 | No | No |
| 16972646 | Pharmaceutical Composition Containing Fusion Protein and Use Thereof | December 2020 | July 2024 | Abandon | 43 | 1 | 1 | No | No |
| 16972357 | Anti-Il-22 Antibodies, Antibody Fragments,Their Immunoconjugates And Uses Thereof | December 2020 | July 2023 | Allow | 32 | 2 | 1 | Yes | No |
| 17109463 | INTERLEUKIN-13 RECEPTOR ALPHA 2 PEPTIDE-BASED BRAIN CANCER VACCINES | December 2020 | June 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17107450 | SINGLE CHAIN Fc FUSION PROTEINS | November 2020 | September 2023 | Abandon | 34 | 1 | 1 | No | No |
| 17097298 | ANTI-IL-6 RECEPTOR ANTIBODY | November 2020 | May 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17097496 | ANTI-INTERLEUKIN-23 P19 ANTIBODIES AND METHODS OF USE THEREOF | November 2020 | April 2022 | Allow | 17 | 0 | 1 | Yes | No |
| 17071046 | METHOD OF TREATING AUTOIMMUNE DISEASE WITH ANTIBODIES AGAINST IL-33 | October 2020 | January 2024 | Allow | 39 | 1 | 1 | No | No |
| 17046220 | TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS USING ANTIBODIES THAT BIND INTERLEUKIN-17A (IL-17A) | October 2020 | July 2022 | Abandon | 22 | 0 | 1 | No | No |
| 17036602 | Polypeptides That Bind To IL-17A, IL-17F And/or IL17-A/F and Methods of Treatment Using Same | September 2020 | July 2023 | Allow | 34 | 1 | 1 | Yes | No |
| 17043197 | Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation | September 2020 | August 2024 | Abandon | 47 | 2 | 1 | No | No |
| 17034136 | BLOCKADE OF CCL18 SIGNALING VIA CCR6 AS A THERAPEUTIC OPTION IN FIBROTIC DISEASES AND CANCER | September 2020 | April 2024 | Abandon | 43 | 1 | 1 | No | No |
| 17015029 | METHOD OF TREATING DISEASES USING AN IL-17 RECEPTOR ANTIBODY FORMULATION | September 2020 | July 2022 | Allow | 22 | 1 | 1 | Yes | No |
| 16999470 | Use of Brazikumab to Treat Crohn's Disease | August 2020 | September 2022 | Abandon | 25 | 1 | 1 | No | No |
| 16998597 | DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS | August 2020 | October 2023 | Abandon | 37 | 1 | 1 | No | No |
| 16966237 | MULTISPECIFIC ANTIBODIES AGAINST IL-5 AND IL-4R | July 2020 | October 2023 | Allow | 39 | 2 | 1 | Yes | Yes |
| 16937121 | IL-21 BINDING PROTEINS AND USES THEREOF | July 2020 | May 2023 | Abandon | 33 | 1 | 0 | No | No |
| 16770544 | CHEMOKINE VARIANTS AS IMMUNE STIMULANTS | June 2020 | May 2023 | Abandon | 35 | 1 | 1 | No | No |
| 16892533 | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody | June 2020 | July 2023 | Abandon | 37 | 2 | 1 | Yes | Yes |
| 16880804 | ACE2-Fc Trap | May 2020 | May 2022 | Abandon | 24 | 3 | 1 | Yes | No |
| 16765617 | PARTIAL AGONISTS OF INTERLEUKIN-2, NUCLEIC ACIDS ENCODING SAME, AND METHODS OF USE THEREOF | May 2020 | June 2024 | Abandon | 49 | 2 | 1 | No | No |
| 16860660 | TARGETED MODIFIED IL-1 FAMILY MEMBERS | April 2020 | March 2023 | Abandon | 35 | 1 | 1 | No | No |
| 16856496 | METHODS OF TREATING VIRAL INFECTION WITH A COMPOSITION COMPRISING IL-18 AND IL-22 | April 2020 | August 2022 | Allow | 27 | 1 | 1 | Yes | No |
| 16754799 | COMPOSITIONS COMPRISING MDA-7/IL-24 PROTEIN AND METHODS OF USE | April 2020 | December 2022 | Abandon | 33 | 1 | 1 | No | No |
| 16838415 | ANTIBODY MOLECULES | April 2020 | January 2022 | Abandon | 22 | 0 | 1 | No | No |
| 16824613 | METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS | March 2020 | August 2022 | Allow | 29 | 1 | 1 | Yes | No |
| 16796652 | ACTIVATABLE ANTIBODIES THAT BIND INTERLEUKIN-6 RECEPTOR AND METHODS OF USE THEREOF | February 2020 | October 2022 | Abandon | 32 | 1 | 1 | No | No |
| 16637246 | BISPECIFIC FUSION PROTEIN FOR IL-17 AND TNF-alpha | February 2020 | April 2023 | Abandon | 38 | 2 | 1 | Yes | No |
| 16784173 | IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF | February 2020 | July 2021 | Abandon | 17 | 0 | 0 | No | No |
| 16783339 | NUCLEIC ACIDS ENCODING ANTIBODIES AGAINST IL-1 BETA | February 2020 | April 2022 | Allow | 26 | 1 | 1 | Yes | No |
| 16782541 | ANTIBODIES SPECIFIC FOR IL-21 AND USES THEREOF | February 2020 | August 2022 | Allow | 30 | 2 | 1 | Yes | No |
| 16780588 | TREATMENT OF CANCER BY THE ADMINSTRATION OF AN IL-22BP AND ALBUMIN FUSION | February 2020 | September 2022 | Abandon | 32 | 2 | 1 | No | No |
| 16740747 | Treatment of Genital Psoriasis | January 2020 | August 2022 | Abandon | 31 | 2 | 1 | No | No |
| 16736487 | IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF | January 2020 | July 2021 | Abandon | 18 | 0 | 0 | Yes | No |
| 16720351 | METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS | December 2019 | August 2022 | Allow | 32 | 1 | 1 | Yes | No |
| 16621720 | Protein Kinase C-delta targeted therapy for treating radiation injury | December 2019 | September 2024 | Abandon | 58 | 7 | 1 | Yes | No |
| 16707435 | FUSION PROTEIN COMPRISING IL-4 AND IL-10 | December 2019 | February 2021 | Allow | 14 | 2 | 1 | Yes | No |
| 16700823 | IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF | December 2019 | July 2021 | Abandon | 19 | 0 | 0 | Yes | No |
| 16691012 | NOVEL INTERLEUKIN-17A-SPECIFIC AND INTERLEUKIN-23-SPECIFIC BINDING POLYPEPTIDES AND USES THEREOF | November 2019 | December 2022 | Abandon | 36 | 2 | 1 | No | No |
| 16686921 | COMBINATION OF AN ANTIBODY THAT BINDS TO THE P19 SUBUNIT OF HUMAN IL-23 AND A HYALURONIDASE ENZYME | November 2019 | April 2021 | Abandon | 17 | 0 | 0 | No | No |
| 16614132 | COMPOSITIONS FOR EXPANDING NATURAL KILLER CELLS | November 2019 | March 2024 | Allow | 52 | 2 | 1 | Yes | No |
| 16609726 | SECRETION-COMPETENT MUTEINS OF THE HUMAN IL-27 ALPHA-SUBUNIT | October 2019 | February 2022 | Allow | 27 | 2 | 1 | Yes | No |
| 16663561 | DNA MOLECULES ENCODING ANTI-IL-33 ANTIBODIES | October 2019 | November 2020 | Allow | 13 | 0 | 0 | Yes | No |
| 16607686 | USE OF IL-20 ANTAGONISTS FOR TREATING EYE DISEASES | October 2019 | August 2021 | Allow | 22 | 1 | 1 | Yes | No |
| 16498186 | IL-IR-I BINDING POLYPEPTIDE | September 2019 | June 2024 | Allow | 56 | 4 | 1 | Yes | No |
| 16567646 | Bispecific Anti-TNF-Alpha/IL-17A Antibodies and Anti-TNF-Alpha Antibodies and Methods of Their Use | September 2019 | September 2021 | Abandon | 24 | 0 | 1 | No | No |
| 16564148 | METHOD FOR TREATMENT OF AN IL-17A-MEDIATED DISEASE THROUGH ANTIBODY ADMINISTRATION SPECIFIC TO HUMAN IL-17A | September 2019 | May 2022 | Allow | 32 | 2 | 0 | Yes | No |
| 16491297 | MONOCLONAL ANTIBODY AGAINST BOTH IL-17A AND IL-17F AND USE OF THE SAME | September 2019 | September 2020 | Allow | 13 | 0 | 0 | Yes | No |
| 16555391 | Methods of Treating Palmoplantar Pustular Psoriasis (PPP) Using IL-17 Antibody | August 2019 | February 2022 | Allow | 29 | 1 | 0 | Yes | No |
| 16542135 | COMBINATION THERAPY OF TUMOR-TARGETED IL-2 VARIANT IMMUNOCYTOKINES AND ANTIBODIES AGAINST HUMAN PD-L1 | August 2019 | September 2021 | Abandon | 26 | 0 | 1 | No | No |
| 16510835 | COMPOSITIONS COMPRISING IL-2 FUSION PROTEINS AND METHODS FOR TREATING NEOPLASIA | July 2019 | September 2021 | Abandon | 27 | 1 | 1 | Yes | No |
| 16474913 | VACCINE COMPOSITION COMPRISING A MUTANT OF HUMAN INTERLEUKIN-15 | June 2019 | March 2022 | Abandon | 32 | 2 | 1 | Yes | No |
| 16451426 | Suppression of Microglial Activation with Innate Lymphoid Cells | June 2019 | May 2023 | Abandon | 47 | 4 | 1 | No | No |
| 16440779 | IL-15RALPHA SUSHI DOMAIN - IL-15 FUSION PROTEINS | June 2019 | June 2024 | Allow | 60 | 5 | 1 | Yes | No |
| 16439423 | METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS | June 2019 | December 2021 | Abandon | 30 | 1 | 1 | No | No |
| 16435960 | METHODS OF TREATMENT USING IL-23P19 MONOCLONAL ANTIBODIES | June 2019 | October 2021 | Allow | 29 | 2 | 0 | Yes | No |
| 16415143 | CHEMOKINE-CYTOKINE FUSION PROTEINS AND THEIR APPLICATIONS | May 2019 | July 2023 | Abandon | 50 | 2 | 1 | No | No |
| 16360793 | TARGETED MODIFIED IL-1 FAMILY MEMBERS | March 2019 | April 2023 | Abandon | 49 | 4 | 1 | Yes | No |
| 16357756 | METHODS OF TREATING MALIGNANT TUMOUR WITH IL-12 AND ANTI-PD-1 ANTIBODY | March 2019 | February 2024 | Allow | 59 | 4 | 1 | Yes | Yes |
| 16356309 | USES OF IL-13 ANTAGONISTS FOR TREATING ATOPIC DERMATITIS | March 2019 | May 2022 | Allow | 38 | 3 | 1 | Yes | No |
| 16332900 | ANTIBODY SPECIFICALLY BINDING TO IL-17A, ENCODING NUCLEIC ACID, AND METHOD OF USING THE ANTIBODY | March 2019 | March 2021 | Allow | 25 | 1 | 1 | Yes | No |
| 16272876 | IMMUNOREGULATORY STRUCTURES FROM NORMALLY OCCURING PROTEINS | February 2019 | December 2022 | Abandon | 46 | 4 | 1 | No | No |
| 16319174 | METHODS OF TREATING NEW-ONSET PLAQUE TYPE PSORIASIS USING IL-17 ANTAGONISTS | January 2019 | October 2022 | Abandon | 45 | 2 | 1 | No | Yes |
| 16219177 | THERAPEUTIC USES OF IL-15R ALPHA AND IL-15/IL-15R ALPHA COMPLEXES FOR TREATING CANCER USING CYCLICAL ADMINISTRATION REGIMEN | December 2018 | June 2024 | Abandon | 60 | 4 | 1 | No | Yes |
| 16217130 | Uses of IL-15 Antagonists for the Treatment of Autoimmune and Inflammatory Diseases | December 2018 | January 2021 | Allow | 25 | 0 | 1 | Yes | No |
| 16309072 | ANTI-HUMAN INTERLEUKIN-17A MONOCLONAL ANTIBODY | December 2018 | March 2020 | Allow | 16 | 0 | 0 | Yes | No |
| 16196743 | METHODS OF INHIBITING MICROBIAL INFECTIONS IN THE INTESTINE USING IL-22 Fc FUSION PROTEINS | November 2018 | December 2021 | Abandon | 36 | 2 | 1 | No | No |
| 16196741 | IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE | November 2018 | April 2021 | Abandon | 29 | 1 | 1 | No | No |
| 16196829 | METHODS OF TREATING ACUTE PANCREATITIS USING IL-22 Fc FUSION PROTEINS | November 2018 | June 2021 | Allow | 31 | 1 | 1 | Yes | No |
| 16196936 | METHODS FOR TREATING METABOLIC SYNDROME USING IL-22 Fc FUSION PROTEINS | November 2018 | May 2021 | Allow | 30 | 1 | 1 | Yes | No |
| 16196823 | METHODS FOR PREVENTING OR TREATING CARDIOVASCULAR CONDITIONS USING IL-22 Fc FUSION PROTEINS | November 2018 | May 2021 | Allow | 30 | 1 | 1 | Yes | No |
| 15771310 | METHODS OF TREATMENT USING ANTI-IL-17A/F ANTIBODIES | November 2018 | June 2022 | Allow | 50 | 3 | 1 | Yes | No |
| 16300338 | METHODS OF TREATING DISEASES ASSOCIATED WITH ILC3 CELLS | November 2018 | September 2022 | Abandon | 47 | 3 | 1 | No | No |
| 16181733 | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody | November 2018 | January 2022 | Abandon | 38 | 2 | 1 | Yes | Yes |
| 16099280 | Interleukin Combination and Use Thereof | November 2018 | June 2022 | Abandon | 43 | 2 | 2 | Yes | No |
| 16099093 | THERAPEUTIC COMPOSITIONS AND METHODS WITH CYTOKINE SIGNALING IMMUNOMODULATORS | November 2018 | April 2024 | Allow | 60 | 5 | 1 | Yes | Yes |
| 16095967 | Anti-IL17A autoantibodies for treating or reducing the likelihood of occurrence of bone destruction associated with a chronic autoimmune or inflammatory disease | October 2018 | February 2023 | Allow | 52 | 4 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner JIANG, DONG.
With a 30.8% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 11.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner JIANG, DONG works in Art Unit 1646 and has examined 830 patent applications in our dataset. With an allowance rate of 32.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner JIANG, DONG's allowance rate of 32.7% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by JIANG, DONG receive 2.17 office actions before reaching final disposition. This places the examiner in the 73% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by JIANG, DONG is 34 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +56.3% benefit to allowance rate for applications examined by JIANG, DONG. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 10.1% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 27.1% of cases where such amendments are filed. This entry rate is in the 29% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 80.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 60% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 72.3% of appeals filed. This is in the 56% percentile among all examiners. Of these withdrawals, 67.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 50.4% are granted (fully or in part). This grant rate is in the 62% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 4.2% of allowed cases (in the 87% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.